1-0_HOME-LANDING_CAROUSEL-4

In collaboration with ACD’s COVID-19 Taskforce, College continues to ensure that sensible and appropriate advice is delivered to Fellows, trainees and patients. Information will be updated as developments occur.

College encourages Fellows to stay up to date with government advice and apply this practically. For the most updated COVID-19 information, please refer to the Department of Health website or your relevant State/Territory website.

COVID-19 Vaccination

Latest updates (as of October 14th, 2021)

On 8th October, ATAGI recommended a third dose of COVID-19 vaccines for people who are severely immunocompromised.  Read the statement here.

On 4 September 2021, the TGA provided provisional approval of the Moderna COVID-19 vaccine – Spikevax (elasomeran) – for use in people aged 12 years and over. The Pfizer-BioNTech – Comirnaty vaccine is also provisionally approved for this age group.

Current recommendations and information on COVID-19 vaccines by ATAGI and the TGA are available here:

Therapeutic Goods Administration – COVID-19 Vaccine Weekly Safety Report (External link)

TGAWeekly update

ATAGI COVID-19 vaccination statements, joint statements and weekly updates including on TTS; in outbreak settings; in pregnant women; and in children (External link)

ATAGI9 Aug 2021

ATAGI recommendations on the use of COVID-19 vaccines in all young adolescents in Australia

ATAGI27 Aug 2021
Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca (Patient information. External link)Department of Health30 Jun 2021

For the latest information on COVID-19 vaccinations, visit the Department of Health’s COVID-19 vaccination website. You can also subscribe for the COVID-19 vaccination updates.

College has also developed some COVID-19 information for patients, including COVID-19 vaccinations.

Guidance on COVID-19 vaccinations in dermatology patients on immunomodulatory and biologic agents was published in the Australasian Journal of Dermatology in March 2021. 

The article by the Australasian Medical Dermatology Group makes preliminary recommendations around COVID-19 vaccination in these patients. 

In summary:

  • Vaccination against COVID-19 is strongly encouraged for all patients on immunomodulatory drugs and/or biologic agents.
  • There is currently insufficient data to recommend one COVID-19 vaccine or vaccine type over another.
  • No specific additional risk in patients on immunomodulatory or biologic therapies has so far been identified.
  • Data on vaccine efficacy in patients on these therapies is missing, so standard vaccination protocols are recommended until otherwise advised.

Resource

Source

Updated

SARS‐CoV‐2 (COVID‐19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group (External Link)

Australasian Journal of Dermatology

30 Mar 2021

COVID-19 provider guide for patients with immunocompromise (External Link)

ATAGI

2 Aug 2021

COVID-19 vaccination decision guide for people with immunocompromise (For patients. External Link)

ATAGI

2 Aug 2021

COVID-19 vaccine information for people on an immunosuppressive or biological treatment (For patients. PDF)

Skin Health Institute

Mar 2021

COVID-19 vaccination for pregnant women: Joint Statement between the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) and ATAGI (External Link)

RANZCOG & ATAGI

9 Jun 2021

 

The following Australian Government webpages provide information for employers on workplace rights and obligations when it comes to COVID-19 vaccinations for employees which Fellows may find helpful.

Resource

Source

COVID-19 vaccinations: workplace rights and obligations provides comprehensive information and includes relevant state and territory health orders (External link)

Fair Work Ombudsman

State and territory workplace health and safety bodies websites (External link)

Fair Work Ombudsman

COVID-19 vaccinations and your business understanding your workplace rights and obligations (External Link)

Business.gov.au

Clinical Care and Service Provision

Resource

Source

Updated

COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement (Wang C et al. Australasian Journal of Dermatology)

ACD

9 Apr 2020

COVID-19 – Information for patients receiving immunosuppressive medication (Patient factsheet, PDF)

ACD

24 Mar 2020

COVID-19 – Information for patients receiving biologic medication (Patient factsheet, PDF)

ACD

24 Mar 2020

Guidance on the use of immunosuppressive agents during COVID-19 (External link)

American Academy of Dermatology

Ongoing

Department of Health – Definition of people at risk for serious illness from COVID-19 (External link)

Federal Department of Health

Ongoing

COVID-19 advice for people with chronic health conditions (External link)

Federal Department of Health

Ongoing

Resource

Source

Updated

Clinical Service Provision guidance (PDF) including continuity of care, consultations, prescriptions, letters and referrals, phototherapy, immunosuppressive and biologic medications.

ACD

20 Apr 2020

Delivering care by telehealth (ACD webpages)

ACD

Ongoing

MBS COVID-19 Telehealth items (External link)

MBS OnlineOngoing

Providing health care remotely during COVID-19 (External link) includes telehealth services, prescriptions, home delivery of medicines.

Federal Department of HealthOngoing

Resource

Source

Updated

Work permissions and restrictions framework for workers in health care settings (External link)

Department of Health

8 Oct 2021

The following third-party information has been provided without charge and is high level and general in nature. College strongly recommends Fellows seek specific guidance from their own accountants, advisers and indemnity groups who can tailor advice to their particular practice, financial position and business model.

Resource

Source

Updated

William Buck’s COVID-19 Resource Centre (External link) provides guidance on government subsidies and other financial matters and is specifically curated with business owners and operators in mind.  

William Buck (ACD’s current auditor)

Ongoing

Federal, State & Territory Government Links

College News – CPD & Training Program

The 2021 Training Program has commenced. Updated changes, including 2021 COVID-19 implications, are listed in CONNECT and in the handbook.

Information is subject to change. Please continue to visit this webpage and the ‘All Trainees’ CONNECT group (‘COVID update’ thread).

Trainee Wellbeing

The Trainee Wellbeing and Engagement teamwork to ensure that all trainees have a voice and receive the support they need throughout the training program.

Engagement Officers Ashleigh Thomas (QLD and NSW) and Caterina De Meneghi (VIC, SA, WA, TAS and NT) provide support and advocacy to all trainees including IMGs and PTCs. They also have regular contact with Faculty Directors of Training and Supervisors and work closely with the Trainee Representative Committee to develop relevant initiatives for trainees and address concerns brought forward.

The Engagement Officers assist with reasonable adjustments and ensure that all communication with trainees is kept confidential.

Visit ACD’s Support webpage for more information.